This site uses cookies to improve your experience. By viewing our content, you are accepting the use of cookies. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country we will assume you are from the United States. View our privacy policy and terms of use.

Remove 05 10 fda-outlines-benefit-risk-approach-to-drug-or-biologic-product-quality-assessment
Remove 2022 Remove Article Related Topics
HIV Treatment and Prevention Agents Process Improvement Health Compliance Dosage Compounding Documentation Adverse Reactions Pharmaceutical Companies Packaging Communication More Related Topics >
article thumbnail

Removing Regulatory Hurdles for Continuous Pharmaceutical Manufacturing

ISPE

JULY 5, 2023

This article discusses how US regulators addressed the regulatory hurdles related to CM to broaden its adoption through engagement, regulatory science, guidance, and international harmonization. For pharmaceuticals, however, the continuous production volume, and hence runtime, is flexible to meet variable market demand.

FDA 52
FDA Dosage Documentation Pharmaceutical Companies 52
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

 

Stay Connected

Join 18,000+ Insiders by signing up for our newsletter

About
About
Editions
Editions
Topics
Powered by Aggregage | Terms and Conditions | Your California Rights and Privacy Policy
© Aggregage 2024